NCT01784978 (SUNRISES) is a Phase 2 clinical trial of Sunitinib in Metastatic Renal Cell Carcinoma, sponsored by Associació per a la Recerca Oncologica, Spain.

Who is sponsoring NCT01784978?

NCT01784978 is sponsored by Associació per a la Recerca Oncologica, Spain.

What drugs are being tested in NCT01784978?

Interventions in NCT01784978: Sunitinib, Everolimus.

What condition does NCT01784978 study?

NCT01784978 studies Metastatic Renal Cell Carcinoma.

Is NCT01784978 still recruiting?

NCT01784978 is currently terminated. Last updated 2 October 2017.

Last reviewed 2017-10-02 · How we verify

NCT01784978: SUNRISES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Terminated Phase 2 Last updated 2 October 2017

What this trial tests

Phase 2 trial testing Sunitinib in Metastatic Renal Cell Carcinoma in 41 participants. Terminated before completion.

Timeline

12 February 2013

Primary endpoint
8 May 2017

8 May 2017

Quick facts

Lead sponsor	Associació per a la Recerca Oncologica, Spain
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	12 February 2013
Primary completion	8 May 2017
Estimated completion	8 May 2017
Sites	10 locations across France, Greece, Spain

Drugs / interventions tested

Sunitinib (sunitinib) — full drug profile →
Everolimus (everolimus) — full drug profile →

Conditions studied

Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →

Sponsor

Associació per a la Recerca Oncologica, Spain

Who can join

18 and older, any sex, with Metastatic Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when progression occurs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Dos Santos C, Tijeras-Raballand A, Serova M, Sebbagh S, et al · · 2015 · cited 14× · PMID 25422908 · DOI 10.1038/bjc.2014.578

Verify or expand the search:

Other trials of Sunitinib

Trials testing the same drug.

NCT07218926 — A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatini · Phase 3 · recruiting
NCT07165418 — A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcino · Phase 3 · not yet recruiting
NCT05773274 — Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe · Phase 2 · recruiting
NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
NCT06032728 — Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Tre · NA · not yet recruiting

Other recruiting trials for Metastatic Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting

Other Associació per a la Recerca Oncologica, Spain trials

Trials by the same sponsor.

NCT03390595 — Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01784978 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Associació per a la Recerca Oncologica, Spain
Last refreshed: 2 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01784978.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing